Background {#Sec1}
==========

Accurate measurements of glomerular filtration rate (GFR) are important in nephrology. Because actual GFR is difficult to measure and expensive when used for screening, GFR is often estimated using serum creatinine (eGFR~Cr~). However, serum creatinine (Cr) is affected by non-GFR determinants such as muscle mass, body size, diet, and nutritional status \[[@CR1]\]. Recently, cystatin C (CysC), which is a 13.3 kDa protein serine protease inhibitor produced by all nucleated cells, was proposed as a marker for estimating GFR \[[@CR2], [@CR3]\]. Because CysC is less influenced by muscle mass than other measures, eGFR with CysC (eGFR~CysC~) may reflect GFR more accurately than eGFR with Cr (eGFR~Cr~) in patients with muscle wasting, chronic disease, and limb amputation \[[@CR1]\]. The Kidney Disease Improving Global Outcomes guidelines for the evaluation of chronic kidney disease (CKD) recommends using eGFR~Cr~ as an initial assessment of renal function, and eGFR~CysC~ as a confirmation of CKD in certain circumstances when eGFR~Cr~ is less accurate, with an evidence level of 2B. eGFR~CysC~ may be also used in adult patients with eGFR~Cr~ of 45--59 ml/min/1.73 m^2^ who do not have markers of kidney damage, with an evidence level of 2C \[[@CR4]\]. Nevertheless, the utility of eGFR~CysC~ and conditions under which eGFR~CysC~ differs from eGFR~Cr~ are unknown.

Intra-individual dynamic change in laboratory measurements provides better prognostic information than cross-sectional data alone \[[@CR5]\]. In this respect, trajectory analysis has been applied to evaluate clinical parameters such as blood pressure \[[@CR6]\], disability and functional decline \[[@CR7], [@CR8]\], and body mass index \[[@CR9]\]. Variability in renal function is commonly observed in clinical settings \[[@CR5]\]. Previously, trajectory analysis of eGFR demonstrated that CKD patients with catastrophic declining patterns had high rates of co-morbidities and mortality \[[@CR10], [@CR11]\].. However, the trajectory patterns of eGFR~CysC~ have not been evaluated. The KNOW-CKD (KoreaN cohort Study for Outcomes in patients With Chronic Kidney Disease), a representative Korean CKD cohort, had traced values of eGFR~CysC~, and we identified certain patients had a discrepancy trend between eGFR~Cr~ and eGFR~CysC~. To identify conditions related to discrepancies, we traced the patterns of both types of eGFR results. To enhance accuracy, both Cr and CysC were measured using calibrations traceable to the international standard reference material.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

Study subjects were selected among participants in the KNOW-CKD, which is a representative prospective Korean pre-dialytic CKD cohort that began enrolling patients in 2011, wherein kidney transplant recipients were not included. The detailed design and method of the KNOW-CKD were described previously \[[@CR12]\]. Briefly, a total of 2238 participants were enrolled in the KNOW-CKD study. Both serum Cr and CysC were measured at baseline, 6 months and 1 year after enrollment, and thereafter once per year. Patients who measured both eGFR~Cr~ and eGFR~CysC~ ≥ 5 times from baseline were included. Patients who died during the follow-up period (*n* = 25) and those without baseline CysC (*n* = 7) were excluded. Consequently, 1069 patients were analyzed in the present study. For sensitivity analysis, we defined another group that included patients for whom clinicians measured both eGFR~Cr~ and eGFR~CysC~ ≥ 4 times (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Flow diagram of the study. eGFR, estimated glomerular filtration rate; Cr, creatinine; CysC, cystatin C

Variable measurements {#Sec4}
---------------------

Data for all of the covariates were collected at the time of enrollment including age, sex, comorbidities (diabetes, hypertension, age-adjusted Charlson comorbidity index), body mass index, body surface area, waist and hip circumference, systolic and diastolic pressures, and laboratory findings including white blood cell count, hemoglobin, platelet count, blood urea nitrogen, uric acid, calcium, phosphorus, alkaline phosphatase, total bilirubin, total cholesterol, low density lipoprotein, high density lipoprotein, triglyceride, fasting glucose, albumin, spot urine protein/creatinine ratio (uPCR), and spot urine albumin/creatinine ratio (uACR).

Blood and random voided urine (if possible, second urine in the morning) were collected. All of the samples were measured at a central laboratory (Lab Genomics, Gyeonggi-do, South Korea). Serum Cr was measured by the Jaffe rate blank method using alkaline picrate in a central laboratory and an assay traceable to isotope dilution mass spectrometry (IDMS) (ADVIA® Chemistry Creatinine 2, Siemens, Germany). Serum CysC was measured with a latex-particle enhanced immunoturbidimetric assay (ADVIA® Chemistry Cystatin C Reagents, Siemens, Germany) with calibration traceable to international reference material \[[@CR13], [@CR14]\]. The eGFR was estimated by serum Cr or/and CysC using the CKD Epidemiology Collaboration (CKD-EPI) equation \[[@CR15]\]. Because of ethical issues and data protection regulations, data that support the findings of the present study cannot be made publicly available.

Statistical analysis {#Sec5}
--------------------

All statistical analyses were carried out using R (version 3.5.2; The R Foundation for Statistical Computing, Vienna, Austria). Continuous and categorical variables were presented as means±standard deviation and proportions, respectively. We used one-way analysis of variance and the χ^2^ test for comparisons of continuous variables and categorical variables, respectively. For trajectory analysis, we applied latent class mixed modeling (lcmm R package) and the R code is provided in the [Supplemental materials](#MOESM1){ref-type="media"}. We calculated the entropy, Akaike's information criteria and Bayesian information criteria for goodness-of-fit statistics and these were described in the [Supplemental materials](#MOESM1){ref-type="media"}. Subsequently, we defined the discrepancy group as having decreasing eGFR~Cr~ but stable eGFR~CysC~ and the agreement group as having both stable eGFR~Cr~ and eGFR~CysC~.

To identify factors related to discrepant trends, Firth's penalized likelihood ratio method was used to account for rare events because of potential bias to the maximum likelihood estimator \[[@CR16]--[@CR18]\]. To identify independent conditions related to discrepant trends, univariate and multivariate logistic regression models with backward elimination method were applied. Adjusted variables in multivariate analysis conducted with or without the stepwise conditional method included age, sex, eGFR calculated with Cr and CysC (eGFR~CrCysC~) that represented a renal function, and variables that had *P*-values \< 0.1 in univariate analysis. Statistical significance was set as *P* \< 0.05 using two-tailed tests.

Ethics statement {#Sec6}
----------------

The study protocol was approved by the Institutional Review Board at each participating clinical center \[Seoul National University Hospital (1104--089-359), Seoul National University Bundang Hospital (B-1106/129--008), Yonsei University Severance Hospital (4--2011-0163), Kangbuk Samsung Medical Center (2011--01-076), Seoul St. Mary's Hospital (KC11OIMI0441), Gil Hospital (GIRBA2553), Eulji General Hospital (201105--01), Chonnam National University Hospital (CNUH-2011-092), and Busan Paik Hospital (11--091)\]. Written informed consent was obtained from each patient. The study was conducted in accordance with the principles of the Declaration of Helsinki.

Results {#Sec7}
=======

Baseline characteristics {#Sec8}
------------------------

Baseline characteristics of total enrolled participants were described in Table [1](#Tab1){ref-type="table"}. The mean age of these patients was 53.2 ± 12.1 years and 646 (60.4%) were male. Patients with diabetes and hypertension comprised 283 (26.5%) and 1031 (96.4%) patients, respectively. Mean values for eGFR~Cr~, eGFR~CysC~, and eGFR~CrCysC~ were 58.5 ± 28.9 mL/min/1.73 m^2^, 58.4 ± 31.2 mL/min/1.73 m^2^, and 58.0 ± 30.6 mL/ min/1.73 m^2^, respectively. Median values for uPCR and uACR were 0.4 g/g (0.1--1.0 g/g) and 272.4 mg/g (49.7--705.1 mg/g), respectively. The numbers of patients with uACR 3000 mg/g and uPCR \> 3 g/g were 30 (2.8%) and 60 (5.6%), respectively. Table 1Baseline characteristics of study participantsVariablesTotal (*n* = 1069)Age (years)53.2 ± 12.1Male (%)60.4Age-adjusted Charlson comorbidity index (%)3.9 ± 1.8 Low (≤3)58.7 Moderate (4--5)27.2 High (6--7)12.3 Very high (≥8)1.8Diabetes mellitus (%)26.5Hypertension (%)96.4Systolic blood pressure (mmHg)126.1 ± 14.6Diastolic blood pressure (mmHg)76.4 ± 10.3Body mass index (kg/m^2^)24.5 ± 3.4Body surface area (m^2^)1.7 ± 0.2Systolic blood pressure (mmHg)126.1 ± 14.0Diastolic blood pressure (mmHg)76.4 ± 10.3Cause of chronic kidney disease (%) Diabetic nephropathy15.4 Non-diabetic nephropathy84.6eGFR (ml/min/1.73 m^2^) eGFR~Cr~58.5 ± 28.9 eGFR~CysC~58.4 ± 31.2 eGFR~CrCysC~58.0 ± 30.6Laboratory findings Hemoglobin (g/dL)13.21 ± 1.85 Blood urea nitrogen (mg/dL) Uric acid (mg/dL)6.90 ± 1.86 Phosphorus (mg/dL) Total bilirubin (mg/dL) Albumin (g/dL)4.26 ± 0.35uPCR (mean, interquartile range)0.4 (0.1--1.0)  \< 0.3 g/g (%)45.0 0.3--0.9 g/g (%)30.6 1.0--3.0 g/g (%)18.8  ≥ 3 g/g (%)5.6uACR (mean, interquartile range)272.4 (49.7--705.1)  \< 30 mg/g (%)19.2 30--299 mg/g (%)33.4  ≥ 300 mg/g (%)47.4ESRD event (%)69.0*eGFR* Estimated glomerular filtration rate; *Cr* Creatinine; *CysC* Cystatin C; *uPCR* Urine protein/creatinine ratio; *uACR* Urine albumin creatinine ratio

Trajectory patterns of eGFR~Cr~ and eGFR~CysC~ {#Sec9}
----------------------------------------------

The relationship between baseline eGFR~Cr~ and eGFR~CysC~ is shown as a Bland-Altman plot (Supplemental Figure [1](#MOESM1){ref-type="media"}). The mean value of difference was 0.148, and standard deviation was 11.327. The correlation coefficient (r) between eGFR~Cr~ and eGFR~CysC~ was 0.93. We identified three distinct trajectory patterns for eGFR~Cr~ (Fig. [2](#Fig2){ref-type="fig"}): two groups with stable eGFR~Cr~ (stable with high eGFR~Cr~ \[SH\] and stable with low eGFR~Cr~ \[SL\]) and one group with decreasing eGFR~Cr~ (D). Trajectories of eGFR~CysC~ also showed similar patterns, with two groups with stable eGFR~CysC~ (SH and SL) and one group with decreasing eGFR~CysC~ (D). Baseline characteristics according to the group of eGFR~Cr~ and eGFR~CysC~ were described in Supplemental Table [1](#MOESM1){ref-type="media"}. Particularly, 69% of the ESRD events were occurred in the decreasing eGFRCr (D) group. We conducted cross-tabulation using these groups (Fig. [3](#Fig3){ref-type="fig"}). Most patients (97.6%; *n* = 1043) were classified into the SL group in eGFR~CysC~, followed by the SH (1.31%, *n* = 14) and D (1.12%, *n* = 12) groups. There were small numbers of patients in the D and SH groups with eGFR~CysC~. Fig. 2Trajectory patterns of eGFR~Cr~ and eGFR~CysC.~ eGFR, estimated glomerular filtration rate; Cr, creatinine; CysC, cystatin C; SH, stable and high eGFR group; SL, stable and low eGFR group; D, decreasing eGFR groupFig. 3Cross-table between trends of eGFR~Cr~ and eGFR~CysC.~ eGFR, estimated glomerular filtration rate; Cr, creatinine; CysC, cystatin C; SH, stable and high eGFR group; SL, stable and low eGFR group; D, decreasing eGFR group

Conditions related to discrepant trends between eGFR~Cr~ and eGFR~CysC~ {#Sec10}
-----------------------------------------------------------------------

Table [2](#Tab2){ref-type="table"} summarizes baseline characteristics according to discrepant trends. The patients in the agreement group were older than those in the discrepancy group. There were no differences in underlying disease, including diabetes and hypertension, or body mass index. Body surface area was greater in the discrepancy group than in the agreement group. Proteinuria values represented by uPCR and uACR and baseline renal function evaluated by eGFR~Cr~, eGFR~CysC~, and eGFR~CrCysC~ were higher in the discrepancy group than in the agreement group. Table 2Baseline characteristics according to discrepancy between the trends of eGFR~Cr~ and eGFR~CysC~Discrepancy\
(*n* = 55)Agreement\
(*n* = 706)*P*Age (years)44.8 ± 10.356.8 ± 10.7\< 0.001Male (%)61.862.20.957Age-adjusted Charlson comorbidity index (%)2.4 ± 1.74.0 ± 1.7\< 0.001 Low (≤3)74.542.9 Moderate (4--5)21.836.5 High (6--7)3.618.1 Very high (≥8)02.4Diabetes (%)27.331.40.622Hypertension (%)98.298.91.000Systolic blood pressure (mmHg)128.0 ± 13.0125.9 ± 14.70.306Diastolic blood pressure (mmHg)78.4 ± 10.775.7 ± 10.10.062Body mass index (kg/m^2^)24.4 ± 4.024.7 ± 3.30.514Body surface area (m^2^)1.8 ± 0.21.7 ± 0.20.036Systolic blood pressure (mmHg)128.0 ± 13.0125.9 ± 14.70.306Diastolic blood pressure (mmHg)78.4 ± 10.775.7 ± 10.10.062Cause of chronic kidney disease (%)0.924 Non-diabetic nephropathy81.880.3 Diabetic nephropathy18.219.7eGFR (ml/min/1.73 m^2^) eGFR~Cr~66.4 ± 16.641.9 ± 15.2\< 0.001 eGFR~CysC~58.2 ± 19.7241.6 ± 17.9\< 0.001 eGFR~CrCysC~61.0 ± 18.340.8 ± 16.1\< 0.001Laboratory findings Hemoglobin (g/dL)13.4 ± 1.712.9 ± 1.90.029 Blood urea nitrogen (mg/dL)20.8 ± 5.820.2 ± 8.6\< 0.001 Uric acid (mg/dL)6.8 ± 1.77.4 ± 1.70.020 Phosphorus (mg/dL)3.5 ± 0.53.6 ± 0.60.041 Total bilirubin (mg/dL)0.7 ± 0.30.7 ± 0.30.087 Albumin (g/dL)4.2 ± 0.34.2 ± 0.30.967uPCR (mean, interquartile range)0.5 (0.2--1.5)0.4 (0.1--1.0)0.054  \< 0.3 g/g (%)30.941.30.011 0.3--0.9 g/g (%)27.333.1 1.0--3.0 g/g (%)27.320.6  ≥ 3.0 g/g (%)14.55.0uACR (mean, interquartile range g)427 (120--1206)295 (72--744)0.040  \< 30 mg/g (%)7.314.50.202 30--299 mg/g (%)32.736.1  ≥ 300 mg/g (%)60.049.4*eGFR* Estimated glomerular filtration rate; *Cr* Creatinine; *CysC* Cystatin C; *uPCR* Urine protein/creatinine ratio; *uACR* Urine albumin creatinine ratio

When the discrepancy group was set as the dependent variable, younger age and proteinuria were selected as predictors of discrepancies between trends of eGFR~Cr~ and eGFR~CysC~. When the backward elimination method was applied (model 2 in Table [3](#Tab3){ref-type="table"}), age and proteinuria remained significant for predicting the discrepancy of trends. These results remained consistent in the subgroup analyses according to the age and proteinuria (Supplementary Tables [4](#MOESM1){ref-type="media"}, [5](#MOESM1){ref-type="media"}). Table 3Analysis to identify conditions related to discrepant trends of eGFR~Cr~ and eGFR~CysC~Model 1Model 2VariablesOR (95% CI)*P*OR (95% CI)*P*Age0.92 (0.89--0.95)\< 0.0010.92 (0.89--0.95)\< 0.001Male1.60 (0.61--4.26)0.343Age-adjusted CCI Low (≤3)Reference Moderate (4--5)1.30 (0.53--3.12)0.563 High (6--7)1.66 (0.28--7.28)0.541 Very high (≥8)2.48 (0.02--30.54)0.608Body surface area2.01 (0.18--20.83)0.562Diastolic blood pressure1.01 (0.98--1.04)0.579Hemoglobin0.90 (0.71--1.13)0.350Blood urea nitrogen0.99 (0.92--1.05)0.661Uric acid0.91 (0.74--1.12)0.379Phosphorus0.83 (0.42--1.62)0.590Total bilirubin2.00 (0.52--7.35)0.307uPCR (g/g)  \< 0.3ReferenceReference 0.3--0.91.69 (0.49--5.26)0.3921.53 (0.68--3.45)0.305 1.0--3.04.54 (0.95--21.44)0.0583.32 (1.43--7.84)0.006  ≥ 3.017.87 (3.14--102.19)0.00112.38 (4.07--37.39)\< 0.001uACR (mg/g)  \< 30Reference 30--2992.53 (0.74--10.73)0.145  ≥ 3001.55 (0.27--10.19)0.630eGFR~CrCysC~1.07 (1.04--1.10)\< 0.0011.07 (1.05--1.09)\< 0.001Model 1: Adjusted for age, sex, eGFR~CrCys~ and the variables which had *P* value less than 0.1 in univariate analysisModel 2: Model 1 with backward elimination method*CCI* Charlson comorbidities index; *OR* Odds ratio; *CI* Confidence interval; *uPCR* Urine protein/creatinine ratio; *uACR* Urine albumin/creatinine ratio; *eGFR*, estimated glomerular filtration rate; *Cr* Creatinine; *CysC* Cystatin C

Sensitivity analysis with patients for whom eGFRs were measured ≥4 times {#Sec11}
------------------------------------------------------------------------

The sensitivity analysis was conducted in patients for whom eGFRs were measured more than 4 times (*n* = 1451). The results for most baseline features were similar to those of the previous patient group (Supplemental Table [6](#MOESM1){ref-type="media"}). Their mean age was 53.2 ± 12.1 years old and 59.5% of enrolled patients were male. Diabetic patients accounted for 29.3%. Mean values of eGFR~Cr~, eGFR~CysC~ and eGFR~CrCysC~ were 57.5 ± 29.6 mL/min/1.73 m^2^, 57.1 ± 31.4 mL/min/1.73 m^2^, and 56.9 ± 31.1 mL/ min/1.73 m^2^, respectively.

The trajectory patterns of eGFR~Cr~ and eGFR~CysC~ were classified into 3 groups (Supplemental Figure [1](#MOESM1){ref-type="media"}), and there were discrepancies between trends similar to those observed in the main analysis (Supplemental Figure [2](#MOESM1){ref-type="media"}). In multivariate analysis, young patient age, proteinuria, and other variables such as male sex and large body surface area had tendencies for discrepancy compared with the counterpart groups (Supplemental Table [7](#MOESM1){ref-type="media"}).

Discussion {#Sec12}
==========

Information about eGFRs trends may be more helpful to predict prognosis than single measurements of eGFR. Although CysC has been used as an additional parameter to calculate GFR, eGFR~CysC~ trends have not been evaluated and compared to those of eGFR~Cr~. In the present study, we first compared eGFR~Cr~ and eGFR~CysC~ trends and found that certain factors such as young age and proteinuria were related to discrepancies in trends between two eGFRs.

In the present study, we identified young age as a condition related to discrepancies between two eGFR trends, and the possible mechanisms are described as follows. There was a non-linear association between age and CysC concentration \[[@CR19]\], and the increment rates of CysC levels were accelerated in patients aged over 50--60 years \[[@CR20], [@CR21]\]. Serum Cr remained relatively constant in healthy individuals between 20 and 70 years old \[[@CR22]\]. Because there is a gap between the time point of increasing Cr and CysC, age may be a factor underlying discrepancies between eGFR trends. Additionally, when the CKD-EPI equation was developed, a large number of young patients were included from various diabetic cohorts \[[@CR23]\], so that the proportions of younger diabetic patients differed from those in more recent studies (≤40 years, 11%; and 41--50 years, 20% in the KNOW-CKD cohort vs. ≤40 years, \> 40% in the CKD-EPI-developing cohort). Such baseline differences might affect the non-GFR determinants of CysC because CysC is associated with insulin resistance, obesity, hypertension, and oxidative stress, which in turn are closely dependent on diabetes \[[@CR24]--[@CR26]\]. Inflammation could be a reason for the discrepancy between trends of eGFR~Cr~ and eGFR~CysC~, as inflammation is a representative determinant of CysC \[[@CR27]\]. Although a wide ranges of inflammatory markers were not measured in the study cohort, young and old participants might have different inflammatory milieu that affects eGFR~CysC~ trends. Because these hypotheses have not been thoroughly tested, further evaluations regarding the mechanisms underlying this phenomenon are needed.

Most filtered CysC is reabsorbed and metabolized by the proximal tubule cells \[[@CR28], [@CR29]\]. Previous study identified that the concentration of CysC was influenced by urine protein excretion, an influence stronger than that of Cr \[[@CR30]\]. Similarly, several studies suggest that heavy proteinuria influenced renal handling of CysC \[[@CR31], [@CR32]\]. The association between urinary CysC and proteinuria was predominant in pediatric cases with nephrotic syndrome compared with controls \[[@CR32]\]. Proteinuria itself decreases the tubular uptake of low molecular weight proteins, including CysC, primarily throughout the competition for a common transport mechanism in the preclinical model \[[@CR31]\]. The present findings regarding the relationship between proteinuria and discrepant trends might be attributable to these factors.

Non-GFR determinants are well-known for serum Cr and CysC, respectively. A representative non-GFR determinant for Cr is muscle mass. Body mass index is a simple index for body composition but does not distinguish between excess fat, muscle, and bone mass \[[@CR33], [@CR34]\]. In the present study, we did not detect the independent significance of body mass index underlying the discrepancy between eGFR trends, although a dependent relationship with body surface area was detected. This difference might be because body mass index and body surface area do not reflect muscle mass. In the present study, the mean body mass index was 24.5 ± 3.4 kg/m^2^, which was lower than that of another CKD cohort (32.1 ± 7.9 kg/m^2^ in CRIC) \[[@CR35]\]. In this respect, population-related factors also hamper the distinctive relationship between body mass index and muscle mass and thus, the effects of body mass index and body surface area might disappear in the final analysis.

The study has some limitations that deserve attention. The number of subjects was modest, although the statistical power was sufficient. Particularly, we could not compare the discrepant trends between some groups with low patient numbers. The study sample was entirely comprised of East Asians and CKD-EPI eGFR equations were not validated in the Korean population. As noted above, non-eGFR~Cr~ determinants such as muscle mass differed from those of individuals of European descent, which warrants further study to identify other significant conditions. The present findings were obtained from patients with non-dialytic CKD, and thus, the application of results to healthy individuals or the general population is limited. Standard measurements of GFR such as inulin excretion rate were not available for the study cohort, and such data would be useful to determine which trend was more accurate.

The results of the present study demonstrate discrepant conditions between trends from eGFR~Cr~ and eGFR~CysC~. Although further studies are needed to confirm our findings in other independent cohorts, clinicians should remain aware that discrepant conditions may occur when both Cr and CysC are used to evaluate and trace renal function. Because the present guidelines do not urge caution when determining the condition of eGFR~CysC~, our results may constitute the basis of future updates.

Conclusions {#Sec13}
===========

In conclusion, we identify conditions related to discrepant trends of eGFR~Cr~ and eGFR~CysC~. Clinicians should remain aware of such potential discrepancies when tracing both Cr and CysC.
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:   Stable with high eGFR
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**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Eunjeong Kang and Seung Seok Han co-first authors

Supplementary information
=========================

**Supplementary information** accompanies this paper at 10.1186/s12882-020-01932-4.

Not applicable.

Financial disclosure {#FPar1}
====================

The authors have nothing to disclose.

Conflict of interest {#FPar2}
====================

The authors have nothing to disclose.

Declarations {#FPar3}
============

Nothing to declare.

Study design: SSH, KHO and CA, Acquisition of Data: SKP, WC, YKO, DWC, YSK, and KHO, Data analysis: EK, SSH and JK, Writing the manuscript: EK and SSH, Review, revision and final approval: SSH and KHO. All authors have read and approved the manuscript.

This study was supported by the research program funded by the Korea Center for Disease Control and Prevention (2011E3300300, 2012E3301100, 2013E3301600, 2013E3301601, 2013E3301602, and 2016E3300200). The study was supervised by the CKD Advisory Committee composed of members from the KCDC and the Korean Society of Nephrology (KSN, [NCT01630486](https://clinicaltrials.gov/ct2/show/NCT01630486) at <http://www.clinicaltrials.gov>). The funders had no role in study design, data collection or analysis, decision to publish, or preparation of the manuscript.

The dataset can be available that is within the perspective of the scientific objectives of KNOW-CKD and researchers who approved by the KNOW-CKD investigators can be accessed the data (<http://www.know-ckd.org/ckd/main/main.html>).

The study protocol was approved by the Institutional Review Board at each participating clinical center \[Seoul National University Hospital (1104--089-359), Seoul Navtional University Bundang Hospital (B-1106/129--008), Yonsei University Severance Hospital (4--2011-0163), Kangbuk Samsung Medical Center (2011--01-076), Seoul St. Mary's Hospital (KC11OIMI0441), Gil Hospital (GIRBA2553), Eulji General Hospital (201105--01), Chonnam National University Hospital (CNUH-2011-092), and Busan Paik Hospital (11--091)\]. Written informed consent was obtained from each patient.

Not applicable.

None.
